Osteonecrosis, Osteonecrosis of the Femoral Head
Conditions
Keywords
RAB001, LLP2A-Alendronate, Osteonecrosis of the Femoral Head
Brief summary
This is a multicenter, randomized (similar to drawing lots, where the treatment you receive is not chosen by you or the researchers), controlled, blinded (the three dose groups of the investigational drug are blinded, meaning neither you nor the blinded researchers will know which dose you are receiving) clinical study to evaluate the efficacy, safety, and PK/PD profiles of RAB001 for injection in patients with early-stage non-traumatic osteonecrosis caused by long-term glucocorticoid use. A parallel-group enrollment design will be used, with a total of approximately 160 subjects expected to be enrolled (High-dose A: 1200 μg/kg；Medium-dose B: 750 μg/kg ；Low-dose C: 400 μg/kg): Control group (D: Alendronate Sodium Tablets (Fosamax) 70 mg orally once weekly) = 40 cases . If you agree to participate in this trial, you will have a 25% chance of being assigned to one of the groups mentioned above. Supportive treatment: Calcium (recommended dose: 1000-1200 mg/d) + Vitamin D (recommended dose: 600-800 IU/d). The study physician may choose the appropriate dosage of calcium and vitamin D based on the subject's specific conditions. Primary endpoints: 1. . Change in femoral head necrotic lesion volume at 48 weeks (MRI) 2. . Change in hip function score at 48 weeks (HHS, Harris Hip Score)
Interventions
DRUGRAB001 high dose
Intravenous infusion RAB001 1200μg/kg
Intravenous infusion RAB001 750μg/kg
DRUGRAB001 low dose
Intravenous infusion RAB001 400μg/kg
Alendronate 70mg weekly
Sponsors
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* 18 years ≤ age ≤ 69 years, gender not limited; * Patients with glucocorticoid-induced osteonecrosis of the femoral head (ONFH) according to the 2019 edition of the "Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults", with an ARCO stage of II, and confirmed by CT and MRI examinations to have no femoral head collapse, and the time from first glucocorticoid use to the screening period must exceed 30 days; * The participant has no plans for hip surgery on the target side within the next 54 weeks; * Participants with unilateral or bilateral ONFH are not restricted. For unilateral involvement, the affected side (as the target side) must have no femoral head collapse confirmed by hip CT examination. For bilateral involvement, hip CT examination must confirm that at least one side has no collapse (the non-collapsed side is the target side; if both sides are necrotic and neither has collapsed, the side with more severe necrosis is the target side. If the contralateral side of the target side meets the criteria for study-defined osteonecrosis, all study information must be recorded for that side as for the target side); * Participants must be informed about the study and voluntarily sign a written informed consent form before the trial.
Exclusion criteria
* BMI ≥ 35 kg/m²; * The target-side osteonecrosis of the femoral head (ONFH) is classified as type M according to the China-Japan Friendship Hospital (CJFH) classification; * Inability to walk or to complete all the examinations, treatments, and follow-ups required by the trial protocol; * Currently receiving glucocorticoid pulse therapy; * Severe metabolic diseases, cardiovascular diseases, clinically significant atrial fibrillation, uncontrolled hypertension, uncontrolled asthma, symptomatic pulmonary fibrosis, recent gastrointestinal bleeding requiring transfusion, mental or psychological disorders; * History of deep vein thrombosis, with any invasive preventive/therapeutic measures taken within the last five years; * Current fracture or infection in either hip joint, or previous surgery on the target-side hip joint; * Planned oral surgery within 54 weeks after enrollment; * Known hereditary bone diseases, such as achondroplasia, osteogenesis imperfecta, hypophosphatemic rickets, etc.; * Use of medications for bone metabolic diseases, integrins, α4β1 inhibitors/antagonists, or anti-VEGF drugs within 6 months or 5 half-lives (whichever is longer) prior to screening, as detailed in section 12.7; * Participants who have received opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), or other pain medications within 5 half-lives prior to screening; * Comorbidities that, in the investigator's judgment, may affect the clinical efficacy assessment of the hip joint, such as knee osteoarthritis, scoliosis, pelvic or lower limb deformities, etc.; * Previous allergy or contraindication to alendronate; * Any of the following abnormal laboratory findings during screening: Phosphate level \< LLN; Patients with decompensated liver function (e.g., complications of portal hypertension such as ascites, gastroesophageal variceal bleeding, sepsis, hepatic encephalopathy, hepatorenal syndrome, etc.); Estimated glomerular filtration rate (eGFR) \< 35 mL/min/1.73 m² (calculated based on creatinine using the CKD-EPI Creatinine 2009 Equation); Hemoglobin \< 100 g/L; Prolonged QT interval (male \> 450 msec, female \> 470 msec). * Donation or loss of blood/plasma \> 400 mL within 3 months prior to screening (except for physiological blood loss in females); * History of drug abuse within 2 years prior to screening; * History of substance abuse within 2 years prior to screening; * Pregnant or breastfeeding women, or female participants who have had unprotected sexual intercourse within 6 weeks prior to screening, or female participants with a positive blood pregnancy test; participants (or their partners) planning to conceive or donate sperm/eggs during the trial and for 6 months after study completion, or unwilling to use one or more contraceptive methods during the trial and for 6 months after study completion; * Participation in other drug clinical trials with medication use within 3 months prior to screening; * Participants deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Necrotic Area Volume of the Femoral Head (MRI) | week48 | — |
| Changes in Hip Function Scores (HHS) | week48 | It is a clinical tool widely used to assess hip function and pain levels. The scoring system is administered by physicians through questionnaires and physical examinations, covering multiple dimensions such as pain, function, deformity, and range of motion.Higher scores indicate milder symptoms in patients, with a maximum of 100 points and a minimum of 0 points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the volume of the femoral head necrotic area (MRI) | week24 | — |
| Changes in Hip Function Scores (HHS) | week24 | It is a clinical tool widely used to assess hip function and pain levels. The scoring system is administered by physicians through questionnaires and physical examinations, covering multiple dimensions such as pain, function, deformity, and range of motion.Higher scores indicate milder symptoms in patients, with a maximum of 100 points and a minimum of 0 points. |
| Changes in bone mineral density (DEXA) of the proximal femur (total hip) and lumbar spine (L1-L4) | week24and week48 | — |
| Rate of non-collapse of the femoral head(defined as femoral head collapse ≤ 2mm based on hip CT + MRI examination) | week24 and week48 | — |
| Time to progression of osteonecrosis in the target-side femoral head compared to baseline (defined as femoral head collapse > 2mm based on hip CT + MRI examination) | week48 | — |
| Changes in WOMAC scores | week24 and week48 | The WOMAC score is one of the most widely used tools in hip or knee osteoarthritis research and clinical practice. It comprises three subscales: Pain, Stiffness, and Physical Function. Lower scores indicate milder symptoms in patients, with the scale ranging from a minimum of 0% to a maximum of 100%. |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | week 48 | — |
| Incidence of anti-drug antibodies (ADA) | week1、week7、week25、week49 week53 | — |
Countries
China
Outcome results
None listed